Autolus Therapeutics
AUTLInstitutional ownership · Q2 2026
Institutional holders
83
Unchanged vs Q1 2026
Reported value
$212.0M
+15.0% vs Q1 2026
Shares held
132.2M
-2.2M shares
Quarter
Q2 2026
Period ended Jun 30, 2026
83 institutional managers reported holding 132,203,060 shares worth $211,968,383 on Form 13F for Q2 2026, against 83 in Q1 2026. Share positions on CUSIP 05280R100 only; option legs and principal-amount lines are not counted.
Top 25 institutional holders · Q2 2026
| # | Manager | Shares | Value | % of portfolio | Change | Position page |
|---|---|---|---|---|---|---|
| 1 | MAK CAPITAL ONE LLC | 33,621,487 | $53.8M | 7.54% | — | Position |
| 2 | Blackstone Inc | 20,485,611 | $32.8M | 0.08% | — | Position |
| 3 | Syncona Portfolio Ltd | 16,640,720 | $26.6M | 100.0% | — | Position |
| 4 | ARMISTICE CAPITAL LLC | 15,000,000 | $24.0M | 0.29% | -800.0K | Position |
| 5 | TFG Asset Management GP Ltd | 9,500,000 | $15.2M | 2.39% | — | Position |
| 6 | SCHRODER INVESTMENT MANAGEMENT GROUP | 7,833,282 | $12.9M | < 0.01% | -1.7M | Position |
| 7 | Frazier Life Sciences Management L P | 4,447,910 | $7.1M | 0.15% | — | Position |
| 8 | BNP Paribas Asset Management Holding S A | 3,361,156 | $5.4M | < 0.01% | — | Position |
| 9 | Laurion Capital Management LP | 3,316,626 | $5.3M | 0.14% | — | Position |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 1,984,700 | $3.2M | < 0.01% | -314.8K | Position |
| 11 | Bank of America Corporation | 1,605,092 | $2.6M | < 0.01% | -239.6K | Position |
| 12 | BlackRock Inc | 1,603,458 | $2.6M | < 0.01% | +122.7K | Position |
| 13 | UBS Group AG | 1,516,991 | $2.4M | < 0.01% | +211.2K | Position |
| 14 | MORGAN STANLEY | 1,260,832 | $2.0M | < 0.01% | +319.0K | Position |
| 15 | MILLENNIUM MANAGEMENT LLC | 1,224,818 | $2.0M | < 0.01% | +1.0M | Position |
| 16 | Cetera Investment Advisers | 1,157,324 | $1.9M | < 0.01% | +28.3K | Position |
| 17 | Balyasny Asset Management LLC | 972,748 | $1.6M | < 0.01% | +1.1K | Position |
| 18 | JPMorgan Chase & Co | 913,239 | $1.5M | < 0.01% | -22.2K | Position |
| 19 | Alphabet Inc | 698,262 | $1.1M | < 0.01% | — | Position |
| 20 | CITADEL ADVISORS LLC | 695,890 | $1.1M | < 0.01% | +236.5K | Position |
| 21 | Hennion & Walsh Asset Management Inc | 451,403 | $722.2K | 0.02% | +11.2K | Position |
| 22 | Privium Fund Management B V | 363,430 | $581.5K | 0.11% | — | Position |
| 23 | JANE STREET GROUP LLC | 299,862 | $479.8K | < 0.01% | +54.1K | Position |
| 24 | EDENTREE ASSET MANAGEMENT Ltd | 300,000 | $477.0K | 0.15% | — | Position |
| 25 | XTX Topco Ltd | 287,456 | $459.9K | < 0.01% | +231.1K | Position |
Values as reported on each manager's Q2 2026 Form 13F. Change is in shares against the manager's prior-quarter filing.
13F holders by quarter
| Quarter | Holders | Shares | Value |
|---|---|---|---|
| Q2 2026 | 83 | 132.2M | $212.0M |
| Q1 2026 | 83 -5 | 134.4M | $184.4M |
| Q4 2025 | 88 -7 | 139.2M | $276.9M |
| Q3 2025 | 95 +2 | 144.7M | $233.9M |
| Q2 2025 | 93 -1 | 166.0M | $378.6M |
| Q1 2025 | 94 -15 | 168.1M | $261.0M |
| Q4 2024 | 109 +8 | 168.4M | $395.4M |
| Q3 2024 | 101 -10 | 178.6M | $648.5M |
| Q2 2024 | 111 -10 | 178.2M | $620.0M |
| Q1 2024 | 121 +22 | 175.8M | $1.1B |
| Q4 2023 | 99 +30 | 115.9M | $746.6M |
| Q3 2023 | 69 +1 | 110.8M | $258.1M |
| Q2 2023 | 68 +4 | 109.4M | $260.4M |
| Q1 2023 | 64 -8 | 106.1M | $195.1M |
| Q4 2022 | 72 +10 | 108.2M | $205.5M |
| Q3 2022 | 62 +2 | 49.3M | $105.6M |
| Q2 2022 | 60 -3 | 50.8M | $143.8M |
| Q1 2022 | 63 -6 | 53.2M | $229.4M |
| Q4 2021 | 69 +16 | 48.7M | $252.7M |
| Q3 2021 | 53 | 21.5M | $141.0M |
Q3 2021–Q2 2026, as reported on Form 13F. Earlier quarters are in the ownership explorer below.
Across other SEC filings
Fund holders · N-PORT
8 funds| Fund | Value | % of fund | As of |
|---|---|---|---|
| iShares Biotechnology ETF IBB | $2.3M | 0.03% | Jun 2026 |
| Tema Oncology ETF | $630.1K | 0.3% | Aug 2026 |
| Invesco NASDAQ Future Gen 200 ETF QQQS | $140.4K | 0.62% | Aug 2026 |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF GWX | $135.1K | 0.02% | Jun 2026 |
| ActivePassive International Equity ETF APIE | $74.2K | < 0.01% | Aug 2026 |
| Fidelity Nasdaq Composite Index Fund | $31.4K | < 0.01% | Aug 2026 |
| Invesco Nasdaq Biotechnology ETF IBBQ | $29.2K | 0.03% | Aug 2026 |
| ProShares Ultra Nasdaq Biotechnology BIB | $16.8K | 0.02% | Aug 2026 |
8 funds reported holding $3,343,434 in total on their latest public Form N-PORT reports, the most recent dated August 2026.
Annual & quarterly reports
-
10-K · FY2025 Filed 2026-03-27Business · Risk Factors · Management's Discussion and Analysis
-
10-Q · Q2 FY2026 Filed 2026-08-11Management's Discussion and Analysis · Controls and Procedures · Legal Proceedings · Risk Factors
5%+ holders · 13D/G
3 filers| Filer | % of class | Filed |
|---|---|---|
| ARMISTICE CAPITAL LLC 13G | 5.6% | 2026-08-14 |
| MAK Capital Fund LP 13G | 12.6% | 2026-05-15 |
| Syncona Portfolio Ltd 13G | 10.8% | 2025-05-07 |
Latest Schedule 13D or 13G from each filer naming this CUSIP; stakes a filer has reported closed are left out.
Insiders · Form 4
Net insider transactions, 12 months
-$15.7K
0 filings with purchases ($0),
1 filing with sales ($15.7K)
Latest filings
- Cintia Piccina 2026-09-03 Sell
- William D Young 2026-07-01 Award
- Madduri Ravin Rao 2026-07-01 Award
- Ryan Richardson 2026-07-01 Award
- Elisabeth Leiderman 2026-07-01 Award
Ownership explorer
Loading ownership explorer…
Security Details
| CUSIP | 05280R100 |
|---|---|
| ISIN | US05280R1005 |
| FIGI | BBG00KVT06G6 |
| Symbol | AUTL |
| Type | Adr |
| Class | SPON ADS as filed on 13F |
| Exchange | Nasdaq |
| Company | Autolus Therapeutics |
Identifier History
| Type | Value | From | To |
|---|---|---|---|
| FIGI | BBG00KVT06G6 | 2026-02-07 | Current |
| CUSIP | 05280R100 | 2018-06-30 | Current |
Listing History
| Symbol | Exchange | From | To |
|---|---|---|---|
| AUTL | Nasdaq | 2018-07-18 | Current |